Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | RECQL | P46063 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28403232 | 0.84 | ALDH1A1 (0.42) | ALDH1A1POLBL3MBTL1MAPTRECQL | |
| SCHEMBL14640214 | 0.84 | TP53 (0.55) | ALDH1A1POLBL3MBTL1MAPTRECQL | |
| SCHEMBL8547801 | 0.82 | BRD4 (0.50) | ALDH1A1POLBMAPTCES2CES1 | |
| SCHEMBL743702 | 0.81 | ALDH1A1 (0.52) | ALDH1A1POLBL3MBTL1MAPTRECQL | |
| SCHEMBL2169988 | 0.79 | POLB (0.55) | ALDH1A1POLBL3MBTL1MAPTRECQL | |
| SCHEMBL18421001 | 0.79 | L3MBTL1 (0.49) | ALDH1A1POLBL3MBTL1MAPTRECQL | |
| SCHEMBL14802220 | 0.79 | ALDH1A1 (0.70) | ALDH1A1POLBL3MBTL1MAPTRECQL | |
| SCHEMBL13381401 | 0.76 | ALDH1A1 (0.43) | ALDH1A1POLBL3MBTL1MAPTRAB9A | |
| SCHEMBL14175024 | 0.75 | KDM4E (0.60) | ALDH1A1POLBL3MBTL1MAPTRECQL | |
| SCHEMBL23521363 | 0.74 | POLB (0.50) | ALDH1A1POLBL3MBTL1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516147-B2 | Aldimines and uses thereof | BOSTIK SA (FR) | 2026-01-06 | — | — | US | disclosed |
| EP-4077273-B1 | ALDIMINES AND USES THEREOF | BOSTIK SA (FR) | 2025-04-02 | — | — | EP | disclosed |
| US-20230038642-A1 | ALDIMINES AND USES THEREOF | BOSTIK SA (FR) | 2023-02-09 | — | — | US | disclosed |
| EP-4077273-A1 | ALDIMINES AND USES THEREOF | Bostik SA (FR) | 2022-10-26 | — | — | EP | disclosed |
| CN-112898734-B | Liquid crystal polymer interlocking network and preparation method and application thereof | 中山大学 | 2022-03-15 | — | — | CN | disclosed |
| WO-2021122594-A1 | ALDIMINES AND USES THEREOF | BOSTIK SA (FR) | 2021-06-24 | — | — | WO | disclosed |
| EP-3838891-A1 | ALDIMINES AND USES THEREOF | BOSTIK SA (FR) | 2021-06-23 | — | — | EP | disclosed |
| CN-112898734-A | Liquid crystal polymer interlocking network and preparation method and application thereof | 中山大学 | 2021-06-04 | — | — | CN | disclosed |
| EP-3510994-A1 | PHARMACEUTICAL FORMULATION COMPRISING AN AQUEOUS SUSPENSION OF AN ANDROSTANE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC CONDITIONS | GLAXO GROUP LIMITED (GB) | 2019-07-17 | — | — | EP | disclosed |
| EP-1478340-B1 | Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions | GLAXO GROUP LTD (GB) | 2018-09-12 | — | — | EP | disclosed |
| WO-2003066036-A1 | PHARMACEUTICAL FORMULATION FOR ADMINISTRATION BY INHALATION COMPRISING AN ANDROSTANE DERIVATIVE AND A BETA-2-ADRENORECEPTOR FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC CONDITIONS | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066063-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIOATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003066032-A1 | FORMULATIONS FOR INHALATION | GLAXO GROUP LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
| US-20030144257-A1 | Novel anti-inflammatory androstane derivative compositions | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2003-07-31 | — | — | US | disclosed |
| US-20030109511-A1 | Novel anti-inflammatory androstane derivative compositions | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2003-06-12 | — | — | US | disclosed |
| EP-1305329-A1 | 6.ALPHA.,9.ALPHA.-DIFLUORO-17.ALPHA.-[(2-FURANYLCARBOXYL)OXY]-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT | GLAXO GROUP LIMITED (GB) | 2003-05-02 | — | — | EP | disclosed |
| US-20020177581-A1 | Novel anti-inflammatory androstane derivative | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2002-11-28 | — | — | US | disclosed |
| US-20020173496-A1 | Formulation containing novel anti-inflammatory androstane derivative | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2002-11-21 | — | — | US | disclosed |
| US-20020165211-A1 | Formulation containing anti-inflammatory androstane derivative | GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED (GB) | 2002-11-07 | — | — | US | disclosed |
| WO-2002012265-A1 | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT | GLAXO GROUP LIMITED (GB) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173496-A1 | Formulation containing novel anti-inflammatory androstane derivative | NR5A1, IL1A, CYP17A1 | ALDH1A1 339/4885POLB 1604/4885L3MBTL1 4872/4885 |
| US-20020165211-A1 | Formulation containing anti-inflammatory androstane derivative | NR5A1, HSD17B11, CYP17A1 | ALDH1A1 391/4885POLB 2593/4885L3MBTL1 4851/4885 |
| US-20030109511-A1 | Novel anti-inflammatory androstane derivative compositions | NR5A1, CYP17A1, CYP19A1 | ALDH1A1 1173/4885POLB 3208/4885L3MBTL1 4862/4885 |
| US-20020177581-A1 | Novel anti-inflammatory androstane derivative | NR5A1, IL1R1, ADRB1 | ALDH1A1 525/4885POLB 2692/4885L3MBTL1 4754/4885 |
| US-20030144257-A1 | Novel anti-inflammatory androstane derivative compositions | NR5A1, CYP17A1, CYP19A1 | ALDH1A1 1151/4885POLB 3115/4885L3MBTL1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.